Lorigerlimab
Lorigerlimab Basic information
- Product Name:
- Lorigerlimab
- Synonyms:
-
- Lorigerlimab
- Research Grade Lorigerlimab (DHD17208)
- Research Grade Lorigerlimab
- CAS:
- 2416595-46-3
- MW:
- 0
- Mol File:
- Mol File
Lorigerlimab Usage And Synthesis
Uses
Lorigerlimab (MGD019) is a bispecific IgG4 dual-affinity re-targeting antibody (DART). Lorigerlimab can block PD-1 and CTLA-4, and improves T-cell responses. Lorigerlimab can be used for research of metastatic castration-resistant prostate cancer (mCRPC)[1][2][3].
in vivo
Lorigerlimab (75 mg/kg, i.v.) shows CTLA-4 blockade in in cynomolgus monkeys[2].
Lorigerlimab (10-100 mg/kg, i.v., 4 weeks) is well tolerated in cynomolgus monkeys, and shows a half-life about 7 days[2].
| Animal Model: | Cynomolgus monkeys [4] |
| Dosage: | 75 mg/kg |
| Administration: | i.v. |
| Result: | Increased the Ki67+ T cell fraction, and showed T cell expansion in the spleen. |
References
[1] Jason J. Luke, et al. Lorigerlimab, a bispecific PD-1×CTLA-4 DART molecule in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A phase 1 expansion (exp) cohort. Journal of Clinical Oncology 2023 41:6_suppl, 155-155.
[2] Berezhnoy A, et al. Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule. Cell Rep Med. 2020 Dec 22;1(9):100163. DOI:10.1016/j.xcrm.2020.100163
[3] Trojaniello C, Luke JJ, Ascierto PA. Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy. Front Oncol. 2021 Jun 10;11:670726. DOI:10.3389/fonc.2021.670726
LorigerlimabSupplier
- Tel
- 177-54423994 17754423994
- 2853530910@QQ.com
- Tel
- 027-65317797 15926423062
- 422450190@qq.com
- Tel
- 027-65279366 18108604356
- products@biolabreagent.com
- Tel
- 13720134139 086-15871494362 13720134139
- orders@jknbiochem.com
- Tel
- 0731-13823398 15111215862
- 313359644@qq.com
Lorigerlimab(2416595-46-3)Related Product Information
- Immunoglobulin G1,anti-(human NCA-90 granulocyte cell antigen) (mouse monoclonal IMMU-MN3 g1-chain), disulfide with mousemonoclonal IMMU-MN3 k-chain, dimer (9CI)
- Anselamimab
- Immunoglobulin G1, anti-(human interferon g) (human-mouse monoclonal HuZAF g1-chain), disulfide with human-mouse monoclonal HuZAF light chain, dimer
- Tuvonralimab
- Gancotamab
- Timolumab
- Axatilimab
- Galegenimab
- Zamerovimab
- Lilotomab